Qingyu Luo

14PUBLICATIONS
30CO-AUTHORS
Liquid biopsiesMolecular targetsTumour immunologyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Haematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (14)

|Mar 19, 2026
Live-cell Pick-Seq (LiP-Seq): Interrogating ultra-rare mantle cell lymphoma persistent cells after CART19 therapy.

Ran Xu, Gongwei Wu, Siobhan Rice

|Feb 24, 2026
Targeting de novo pyrimidine synthesis confers vulnerability to copper-mediated ATR inactivation in PARP inhibitor-resistant ovarian cancer.

Yabing Nan, Kunyu Wang, Menghan Hu

|Nov 24, 2025
IRG1/itaconate/NRF2/GSH axis in tumor-associated macrophages drives therapy resistance and immune evasion in BRCA1-deficient breast cancer.

Yabing Nan, Sophie O'keefe, Xiadi He

|Mar 19, 2025
PI3Kγ in leukemia: class IB PI3 kinase reemerges as a cancer-intrinsic target.

Qingyu Luo, Amanda L Fortune, Andrew A Lane

|May 08, 2024
Targetable leukaemia dependency on noncanonical PI3Kγ signalling.

Qingyu Luo, Evangeline G Raulston, Miguel A Prado

|May 03, 2024
OTUB2 silencing promotes ovarian cancer via mitochondrial metabolic reprogramming and can be synthetically targeted by CA9 inhibition.

Yabing Nan, Xiaowei Wu, Qingyu Luo

Pageof 3

Frequent Collaborators

7 joint publications

Zhihua Liu

7 joint publications

Xiaowei Wu

4 joint publications

Yabing Nan

4 joint publications

Andrew A Lane